Loading stock data…
TG Therapeutics, Inc. (TGTX)
$55.74-0.24 (-0.44%)
Market ClosedLast close Sep 8
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
TG Therapeutics, Inc. in the Healthcare sector is trading at $55.74 with a market capitalization of $7.5B. Wall Street consensus targets $69.71 (7 analysts), implying a +25.1% move over the next 12 months. The stock is currently near its 52-week high of $59.30, remaining 42.4% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +25.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $240.34M↑ | $204.92M↑ | $192.57M↑ | $161.71M↑ | $141.15M |
| Gross Profit | $199.14M↑ | $171.41M↑ | $154.43M↑ | $133.62M↑ | $122.21M |
| Operating Income | $21.67M↓ | $34.80M↓ | $50.49M↑ | $29.36M↓ | $34.84M |
| Net Income | $7.78M↓ | $19.78M↓ | $23.04M↓ | $390.89M↑ | $28.19M |
Peer Comparison
JNJUNHPFE
Fundamentals
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMV...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$7.46B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
17.47
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.67
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
74.38%
Volume
Today's trading volume
1.08M
Recent News
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
Kymera Therapeutics (KYMR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
IBD Stock Of The Day, TG Therapeutics, Eyes Breakout After Topping Early Buy Point
TG Therapeutics is Wednesday's IBD Stock Of The Day. Shares of the multiple sclerosis biotech has topped an early entry and is near a breakout.
TG Therapeutics (TGTX) Up 15.1% Since Last Earnings Report: Can It Continue?
TG Therapeutics (TGTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
TGTX Stock Pares Opening Losses After Analyst Dismisses Competition From Novartis
TGTX shares opened lower on Tuesday after Novartis said its drug remibrutinib improved multiple sclerosis in late-stage trials.
TGTX Stock Outperforms 95% of Stocks. Here's Why.
Biotech stock TG Therapeutics is building a cup base after a sell-off in early August. It is testing a key moving average.